Stock comparison
Apellis Pharmaceuticals
Mettler-Toledo International
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
APLS
Apellis Pharmaceuticals
Market cap
$5.25B
Sector
Healthcare
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
Overall winner
Apellis Pharmaceuticals APLS
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | APLS | MTD | Winner |
|---|---|---|---|
| Warren Buffett | 58C | 69B | MTD |
| Benjamin Graham | 79D | 65B | APLS |
| Philip Fisher | 71C | 63C | APLS |
| Peter Lynch | 81C | 66B | APLS |
| Joel Greenblatt | 63C | 68B | MTD |
| Charlie Munger | 67D | 74B | MTD |
| Terry Smith | 65B | 70B | MTD |
Side-by-side metrics
| Metric | APLS | MTD |
|---|---|---|
| Market cap | $5.25B | $22.29B |
| P/E (TTM) | 38.8x | 25.3x |
| EV/EBIT | 96.0x | 21.6x |
| ROIC (TTM) | 18.11% | 36.09% |
| Gross margin | 90.12% | 57.79% |
| Net margin | 12.06% | 21.4% |
| Revenue CAGR 5y | 97.06% | 2.01% |
| EPS CAGR 5y | - | 6.12% |
| Debt / Equity | 1.1x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
APLS leads on
- Revenue CAGR 5y97.06%vs 2.01%+98%
- Gross margin90.12%vs 57.79%+36%
MTD leads on
- Debt / Equity-vs 1.1x+102%
- EV/EBIT21.6xvs 96.0x+77%
- Market cap$22.29Bvs $5.25B+76%
- ROIC (TTM)36.09%vs 18.11%+50%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.